NCT04428788
Recruiting
June 11, 2020
May 5, 2022
Brief summary:
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
N/A
Arm | Intervention/treatment |
---|---|
Experimental: Administration of CC-94676 |
Drug: CC-94676 Specified dose on specified days |
For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit: www.BMSStudyConnect.com Inclusion Criteria: Must have histologically or cytologically confirmed adenocarcinoma of the prostate Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC) Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1 Exclusion Criteria: Prior treatment with an androgen receptor degrader Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 2 years prior to the first dose of study treatment Clinically significant venous thromboembolism (VTE) within 3 months Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness Other protocol-defined inclusion/exclusion criteria apply
Contact: BMS Study Connect Contact Center www.BMSStudyConnect.com 855-907-3286 Clinical.Trials@bms.com
Contact: First line of the email MUST contain the NCT# and Site #.
United States, Florida
Florida Cancer Specialists
Sarasota
United States, Florida
Florida Cancer Specialists
Sarasota
United States, Illinois
University of Chicago
Chicago
United States, Maryland
Johns Hopkins
Baltimore
United States, Massachusetts
Dana Farber Cancer Institute
Boston
United States, Massachusetts
Dana Farber Cancer Institute
Boston
United States, Michigan
START Midwest
Grand Rapids
United States, Michigan
START Midwest
Grand Rapids
United States, New York
Memorial Sloan-Kettering Cancer Center
New York
United States, New York
Memorial Sloan-Kettering Cancer Center
New York
United States, North Carolina
Duke University Medical Center
Durham
United States, Texas
UT Southwestern
Dallas
United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio
United States, Texas
South Texas Accelerated Research Therapeutics
San Antonio
Celgene
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb